EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic ...

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial ...

PITTSBURGH, PA, USA I July 18, 2025 I Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, ...